Evidence map›Paper›PMID 21846410›Full record

ArticleBMC cancer2011

Childhood acute leukemias are frequent in Mexico City: descriptive epidemiology.

María Luisa Pérez-Saldivar, Arturo Fajardo-Gutiérrez, Roberto Bernáldez-Ríos, Armando Martínez-Avalos, Aurora Medina-Sanson, Laura Espinosa-Hernández, José de Diego Flores-Chapa, Raquel Amador-Sánchez, José Gabriel Peñaloza-González, Francisco Javier Alvarez-Rodríguez and 17 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in BMC cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02451774 (SAFETY AND EFFICACY OF PENTOXIFYLLINE VERSUS PLACEBO ADMINISTERED AS APOPTOSIS INDUCTOR DURING REMISSION INDUCTION PHASE OF PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA), which is not on this map. Cited by 62 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 1 pooled it
10.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02451774 phase2 / phase3unknown statusnot on this mapstarted 2015, after this paper: background citation

Safety and efficacy of pentoxifylline versus placebo administered as apoptosis inductor during remission induction phase of pediatric patients with acute lymphoblastic leukemia

TypeinterventionalSponsorRamón Óscar González-Ramella, Ph.DRan2015 to 2020Enrolled44ConditionsAcute Lymphoblastic LeukemiaArmsPentoxifylline Plus Chemotherapy, Placebo Plus Chemotherapy
3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 1 synthesis or guideline pooled it, 168 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Pentoxifylline during steroid window phase at induction to remission increases apoptosis in childhood with acute lymphoblastic leukemia.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2016
    Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Frontiers in oncology · 2024
    Article
  17. Article
  18. Abnormal expression ofBlood research · 2023
    Article
  19. Article
  20. Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 8 institutions in 1 country.

María Luisa Pérez-SaldivarUnidad de Investigación en Epidemiología Clínica, Unidad Médica de Alta Especialidad UMAE Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Instituto Mexicano de Seguridad Social, México DF, México.
Arturo Fajardo-Gutiérrez
Roberto Bernáldez-Ríos
Armando Martínez-Avalos
Aurora Medina-Sanson
Laura Espinosa-Hernández
José de Diego Flores-Chapa
Raquel Amador-Sánchez
José Gabriel Peñaloza-González
Francisco Javier Alvarez-Rodríguez
Victoria Bolea-Murga
Janet Flores-Lujano
María Del Carmen Rodríguez-Zepeda
Roberto Rivera-Luna
Elisa María Dorantes-Acosta
Elva Jiménez-Hernández
Martha Alvarado-Ibarra
Martha Margarita Velázquez-Aviña
José Refugio Torres-Nava
David Aldebarán Duarte-Rodríguez
Rogelio Paredes-Aguilera
María de Los Ángeles Del Campo-Martínez
Rocío Cárdenas-Cardos
Paola Hillary Alamilla-Galicia
Vilma Carolina Bekker-Méndez
Manuel Carlos Ortega-Alvarez
Juan Manuel Mejia-Arangure
Mexican Social Security Institute · MXCentro Médico Nacional La Raza · MXHospital Infantil de México Federico Gómez · MXHospital Juárez de México · MXHospital Pediátrico Moctezuma · MXInstitute for Social Security and Services for State Workers · MXSecretaria de Salud · MXHospital General de México · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWorldwide, acute leukemia is the most common type of childhood cancer. It is particularly common in the Hispanic populations residing in the United States, Costa Rica, and Mexico City. The objective of this study was to determine the incidence of acute leukemia in children who were diagnosed and treated in public hospitals in Mexico City.

methodsIncluded in this study were those children, under 15 years of age and residents of Mexico City, who were diagnosed in 2006 and 2007 with leukemia, as determined by using the International Classification of Childhood Cancer. The average annual incidence rates (AAIR), and the standardized average annual incidence rates (SAAIR) per million children were calculated. We calculated crude, age- and sex-specific incidence rates and adjusted for age by the direct method with the world population as standard. We determined if there were a correlation between the incidence of acute leukemias in the various boroughs of Mexico City and either the number of agricultural hectares, the average number of persons per household, or the municipal human development index for Mexico (used as a reference of socio-economic level).

resultsAlthough a total of 610 new cases of leukemia were registered during 2006-2007, only 228 fit the criteria for inclusion in this study. The overall SAAIR was 57.6 per million children (95% CI, 46.9-68.3); acute lymphoblastic leukemia (ALL) was the most frequent type of leukemia, constituting 85.1% of the cases (SAAIR: 49.5 per million), followed by acute myeloblastic leukemia at 12.3% (SAAIR: 6.9 per million), and chronic myeloid leukemia at 1.7% (SAAIR: 0.9 per million). The 1-4 years age group had the highest SAAIR for ALL (77.7 per million). For cases of ALL, 73.2% had precursor B-cell immunophenotype (SAAIR: 35.8 per million) and 12.4% had T-cell immunophenotype (SAAIR 6.3 per million). The peak ages for ALL were 2-6 years and 8-10 years. More than half the children (58.8%) were classified as high risk. There was a positive correlation between the average number of persons per household and the incidence of the pre-B immunophenotype (Pearson's r, 0.789; P = 0.02).

conclusionsThe frequency of ALL in Mexico City is among the highest in the world, similar to those found for Hispanics in the United States and in Costa Rica.

Indexed as

AdolescentChildChild, PreschoolFemaleHumansImmunophenotypingIncidenceInfantLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, AcuteMaleMexicoPrecursor Cell Lymphoblastic Leukemia-LymphomaSocioeconomic Factors

Identifiers

PMID21846410
PMCPMC3171387
OpenAlexW2097799117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.